AN2 Therapeutics reports Q2 net loss $14.4M; terminates epetraborole Phase 2/3 trial in TR-MAC lung disease

AN2 Therapeutics, Inc.

2024-Q2 EPS reported -$1.04

Cash, equivalents, and investments $104.5M at June 30, 2024; runway through 2027.
Net loss $14.4M in Q2 2024 vs $15.8M in Q2 2023; R&D $12.1M, G&A $3.7M.
Terminated Phase 2/3 EBO-301 trial after sputum culture conversion at Month 6 similar between arms; PRO tool validated.
Plans to advance AN2-502998 into Phase 1 for Chagas disease in 2025 and epetraborole into Phase 2 for melioidosis.
Published study on epetraborole efficacy against M. abscessus mouse lung infection model in Antimicrobial Agents and Chemotherapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.